UNSPSC 51294908: Aceprometazine maleate

This classification denotes the maleate form of an antidepressant agent with the molecular formula C19H22N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 984N9YTM4Y, chemically known as ketone, 10-(2-(dimethylamino)propyl)phenothiazin-2-yl methyl but more generally known as aceprometazine, which bears US NIH Compound Identifier 26035. European Medicines Agency schedules Aceprometazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05214MIG.

UNSPSC 51294908 Aceprometazine maleate is a Commodity code that, based on recent state and local opportunities, encompasses procurement of pharmaceutical products and related health-system supplies rather than aceprometazine specifically. State and local governments are using this code to solicit generic multi-source pharmaceuticals, over-the-counter products, naloxone, and drug deactivation systems through competitive bidding processes. The issuing bodies include state health and human services departments, county health authorities, and multistate cooperative purchasing alliances. Seminole County, Florida and the Texas Health and Human Services Commission represent recent activity, with cooperative purchasing vehicles such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) playing a significant role in aggregating demand across multiple jurisdictions.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County released an IFB on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling intent to establish direct relationships between state pharmacy benefit programs and manufacturers. The Minnesota Multistate Cooperative Purchasing Alliance released an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026. Vendors must meet cGMP certification, Drug Supply Chain Security Act compliance, and maintain relationships with authorized wholesalers; insurance requirements typically include commercial general liability of $2,000,000 to $5,000,000 and professional liability coverage.